Sign Out
Fertility: Teratogenicity studies in both rats and rabbits concluded that AmBisome has no teratogenic potential in these species.
Pregnancy: The safety of AmBisome in pregnant women has not been established. AmBisome should only be used during pregnancy if the possible benefits to be derived outweigh the potential risks to the mother and foetus.
Systemic fungal infections have been successfully treated in pregnant women with conventional amphotericin B without obvious effect on the foetus, but the number of cases reported is insufficient to draw any conclusions on the safety of AmBisome in pregnancy.
Lactation: It is unknown whether AmBisome is excreted in human breast milk. A decision on whether to breastfeed while receiving AmBisome should take into account the potential risk to the child as well as the benefit of breastfeeding for the child and the benefit of AmBisome therapy for the mother.
Continue with Google